98%
921
2 minutes
20
Introduction: Neurodegenerative diseases, such as Alzheimer's Disease (AD), are increasingly prevalent, emphasizing the need for early diagnosis and effective intervention. This study explores the feasibility of using the humanoid robot to administer cognitive assessments for Mild Cognitive Impairment (MCI). Specifically, it evaluates the usability, accuracy, and patient experience of robot-administered cognitive testing compared to traditional assessments conducted by neuropsychologists.
Methods: A total of 100 MCI patients were randomly assigned to two groups: one undergoing the Mini-Mental State Examination (MMSE) with and the other receiving the same test administered by a neuropsychologist. After that participants were submitted to a Satisfaction Questionnaire (SQ) designed to assess their emotional and experiential response to the testing procedure, whether administered by a human or a robot.
Results: The intergroup analysis (EG vs. CG) reveals significant differences in age ( = 0.003) and Total SQ ( = 0.01), and in SQ2 ( = 9.76; df = 1; = 0.002), SQ4 ( = 5.02; df = 1; = 0.02), SQ5 ( = 25.35; df = 1; < 0.001), SQ6 ( = 7.68; df = 1; = 0.006) and SQ7 ( = 7.56; df = 1; = 0.006). Results indicate no significant differences in MMSE scores between the two groups, suggesting comparable cognitive evaluation accuracy. However, participants assessed by reported lower frustration levels and higher satisfaction (90% vs. 40%) compared to those tested by a neuropsychologist. Additionally, 92% of patients in the robot-assisted group expressed willingness to retake the test in the same manner, indicating high acceptability and engagement.
Discussion: These findings suggest that robot-assisted cognitive assessments may enhance patient comfort and accessibility to neuropsychological testing. The integration of Artificial Intelligence (AI) further supports diagnostic accuracy and predictive potential, offering promising avenues for early intervention in neurodegenerative diseases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12402807 | PMC |
http://dx.doi.org/10.3389/fpsyg.2025.1579626 | DOI Listing |
J Alzheimers Dis
September 2025
Paula Costa-Urrutia Medical Affairs, Terumo BCT, Edificio Think MVD, Montevideo, Uruguay.
BackgroundTherapeutic plasma exchange (TPE) with albumin replacement has emerged as a potential treatment for Alzheimer's disease (AD). The AMBAR trial showed that TPE could slow cognitive and functional decline, along with changes in core and inflammatory biomarkers in cerebrospinal fluid.ObjectiveTo evaluate the safety and effectiveness of TPE in a real-world setting in Argentina.
View Article and Find Full Text PDFEndocrine
September 2025
Department of General Medicine, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India.
Eur J Neurosci
September 2025
Institute of Public Health, Riga Stradiņš University, Riga, Latvia.
Evidence suggests that working memory (WM) capacity decreases with age, resulting in cognitive decline. Given the link between aging and reduced hippocampal volume, this study examined whether and how hippocampal volume is associated with WM. 46 participants aged 65-85 years (Mage = 71.
View Article and Find Full Text PDFAnn Clin Transl Neurol
September 2025
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Background: Plasma p-tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p-tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).
Methods: We consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay.
Climacteric
September 2025
Palacios Institute of Women's Health, Madrid, Spain.
For women with mild-to-moderate menopausal symptoms, lifestyle changes and over-the-counter products and services can be beneficial for symptom management, especially for those who are contraindicated or averse to using menopausal hormone therapy (MHT). Lifestyle changes, such as increased exercise and improvements in diet, enhance overall health and are suggested by some low-level evidence - largely from observational studies - to alleviate menopausal symptoms. Over-the-counter dietary and herbal supplements are a popular alternative to MHT.
View Article and Find Full Text PDF